Horizon Pharma (HZNP) Issues Commentary on Express Scripts' (ESRX) Business Practices

Go back to Horizon Pharma (HZNP) Issues Commentary on Express Scripts' (ESRX) Business Practices

Negative Press Doesn't Change UBS View on Horizon Pharma (HZNP)

November 12, 2015 9:14 AM EST

UBS analyst Marc Goodman, published a note on Horizon Pharma (NASDAQ: HZNP) in the wake of negative press:

Express Scripts (NASDAQ: ESRX) is suing Horizon for $140M of owed rebates under a contractual agreement that Horizon... More